Schmid S, et al. - Both intrinsic tumor properties and host factors in the tumor microenvironment, including the presence of immune cells (IC), can influence response to immune checkpoint inhibitors, so researchers performed this retrospective analysis of patients with metastatic non-small cell lung carcinoma (NSCLC) receiving nivolumab in order to test the premise that nivolumab efficacy varies across different metastatic sites. They evaluated the overall response rate (ORR) and organ-specific response rate (OSRR) by analyzing computed tomography scans of patients. The estimated ORR and disease control rate (DCR) were 20% and 45%, respectively. Median overall survival, progression-free survival and duration of response were 11.9, 2.3 and 10.3 months. According to findings, the metastatic location was determinative for the efficacy of immunotherapy. In lymph nodes vs other organ sites such as liver, adrenals and bone, the treatment appeared more active. In patients with otherwise sustained treatment benefit, possible future strategies may include additional local treatment in case of oligoprogression in these organs.